Related Experiment Videos
Managing cancer-related anorexia/cachexia
G Mantovani1, A Macciò, E Massa
1Department of Medical Oncology, University of Cagliari, Italy. mantovan@pacs.unica.it
Drugs
|April 28, 2001
Summary
Cancer-related anorexia/cachexia (CAC) involves complex metabolic and inflammatory factors. Progestogens are effective treatments, while antioxidants show promise in managing this condition.
Area of Science:
- Oncology
- Metabolic Medicine
- Pharmacology
Background:
- Cancer-related anorexia/cachexia (CAC) is a complex syndrome with multifactorial causes.
- It involves metabolic abnormalities, inflammation, and tumor-derived factors, leading to decreased food intake and wasting.
- Understanding these mechanisms is crucial for effective management.
Purpose of the Study:
- To review the mechanisms underlying cancer-related anorexia/cachexia (CAC).
- To examine various management strategies, distinguishing between proven, investigational, and unproven treatments.
- To highlight the role of specific pharmacological agents and supportive therapies.
Main Methods:
- Comprehensive literature review of existing research on CAC mechanisms and treatments.
- Analysis of nutritional, pharmacological, and supportive intervention modalities.
- Inclusion of expert opinion and personal clinical experience with specific agents.
Main Results:
- Progestogens (megestrol, medroxyprogesterone) are identified as the most effective and safest first-line treatments for CAC.
- Investigational agents like thalidomide, pentoxifylline, melatonin, and clenbuterol target cytokine release and muscle wasting.
- Antioxidant agents show promise in combination therapies for counteracting oxidative stress in CAC.
Conclusions:
- Progestogens are recommended as primary therapy for managing cancer-related anorexia/cachexia.
- Further research into agents targeting inflammation and muscle wasting is warranted.
- Development of specific quality of life questionnaires for CAC patients is needed.